$SLDB
Solid Biosciences Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024060034 Filed on May 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $19.46M $18.87M
YoY Change -1.6% -23.38%
% of Gross Profit
Depreciation & Amortization $1.235M $327.0K
YoY Change 75.68% -53.49%
% of Gross Profit
Operating Expenses $27.79M $26.86M
YoY Change 3.52% -16.13%
Operating Profit -$27.79M -$26.86M
YoY Change 3.52% -16.13%
Interest Expense $88.00K $95.00K
YoY Change -95.48% -94.34%
% of Operating Profit
Other Income/Expense, Net $2.716M $2.559M
YoY Change 22.67% 30.56%
Pretax Income
YoY Change
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$25.07M -$24.30M
YoY Change 1.8% -19.18%
Net Earnings / Revenue
Basic Earnings Per Share -$0.61 -$0.64
Diluted Earnings Per Share -$0.61 -$0.64
COMMON SHARES
Basic Shares Outstanding 38.38M 37.76M
Diluted Shares Outstanding 40.93M 38.16M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $190.3M $206.1M
YoY Change 18.77% 11.08%
Cash & Equivalents $95.85M $117.6M
Short-Term Investments $94.41M $88.49M
Other Short-Term Assets $7.344M $8.126M
YoY Change 0.84% 59.49%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $197.6M $214.2M
YoY Change 17.99% 12.38%
LONG-TERM ASSETS
Property, Plant & Equipment $5.438M $6.391M
YoY Change -26.42% -25.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $515.0K $175.0K
YoY Change 184.53% -26.47%
Total Long-Term Assets $33.37M $34.50M
YoY Change -10.4% -11.51%
TOTAL ASSETS
Total Short-Term Assets $197.6M $214.2M
Total Long-Term Assets $33.37M $34.50M
Total Assets $231.0M $248.7M
YoY Change 12.83% 8.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.521M $1.730M
YoY Change -15.06% -69.08%
Accrued Expenses $9.918M $10.33M
YoY Change -5.62% -16.61%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $525.0K $496.0K
YoY Change 25.3% 25.25%
Total Short-Term Liabilities $14.69M $14.34M
YoY Change -7.42% -29.34%
LONG-TERM LIABILITIES
Long-Term Debt $953.0K $1.100M
YoY Change -35.7% -31.08%
Other Long-Term Liabilities $22.10M $22.53M
YoY Change -6.56% -5.8%
Total Long-Term Liabilities $23.05M $23.63M
YoY Change -8.27% -7.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $14.69M $14.34M
Total Long-Term Liabilities $23.05M $23.63M
Total Liabilities $37.74M $37.97M
YoY Change -7.95% -17.11%
SHAREHOLDERS EQUITY
Retained Earnings -$708.1M -$683.1M
YoY Change 14.68% 15.23%
Common Stock $901.4M $893.8M
YoY Change 15.39% 15.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $193.2M $210.7M
YoY Change
Total Liabilities & Shareholders Equity $231.0M $248.7M
YoY Change 12.83% 8.32%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$25.07M -$24.30M
YoY Change 1.8% -19.18%
Depreciation, Depletion And Amortization $1.235M $327.0K
YoY Change 75.68% -53.49%
Cash From Operating Activities -$21.47M -$25.20M
YoY Change -21.84% -9.98%
INVESTING ACTIVITIES
Capital Expenditures $286.0K $149.0K
YoY Change -46.64% -70.55%
Acquisitions
YoY Change
Other Investing Activities -$4.890M -$5.000K
YoY Change -89.75% -100.01%
Cash From Investing Activities -$5.176M -$38.49M
YoY Change -89.27% -203.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.000M 107.2M
YoY Change 91.06%
NET CHANGE
Cash From Operating Activities -21.47M -25.20M
Cash From Investing Activities -5.176M -38.49M
Cash From Financing Activities 5.000M 107.2M
Net Change In Cash -21.64M 43.56M
YoY Change -70.38% 370.15%
FREE CASH FLOW
Cash From Operating Activities -$21.47M -$25.20M
Capital Expenditures $286.0K $149.0K
Free Cash Flow -$21.75M -$25.35M
YoY Change -22.31% -11.06%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001707502
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1
0
CY2023 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel1
0
CY2024Q1 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1
0
CY2023 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel1
0
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-38360
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Solid Biosciences Inc.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-0943402
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
500 Rutherford Avenue
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Third FloorCharlestown
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02129
CY2024Q1 dei City Area Code
CityAreaCode
617
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
337-4680
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock $0.001 par value per share
CY2024Q1 dei Trading Symbol
TradingSymbol
SLDB
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
38379413
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117574000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
74015000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
88492000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
49625000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8126000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6094000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
214192000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
129734000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26098000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26539000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6391000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6624000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
175000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
209000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2024Q1 us-gaap Assets
Assets
248689000
CY2023Q4 us-gaap Assets
Assets
164939000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1730000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2032000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10327000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10137000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1694000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1855000
CY2024Q1 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
496000
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
469000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
92000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
24000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
14339000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14517000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22526000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22707000
CY2024Q1 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1100000
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1234000
CY2024Q1 us-gaap Liabilities
Liabilities
37965000
CY2023Q4 us-gaap Liabilities
Liabilities
38458000
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37833689
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37833689
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20386606
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20386606
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
38000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
20000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
893746000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
785199000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
15000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-683056000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-658753000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
210724000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
126481000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
248689000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
164939000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18873000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24631000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7989000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7399000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
26862000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
32030000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-26862000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-32030000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
2651000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1799000
CY2024Q1 us-gaap Interest Expense
InterestExpense
95000
CY2023Q1 us-gaap Interest Expense
InterestExpense
121000
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
282000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2559000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1960000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-24303000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-30070000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.54
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.54
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38155373
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38155373
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19567635
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19567635
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-24303000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-30070000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-19000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
73000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-24322000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-29997000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
126481000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1611000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
4407000
CY2024Q1 sldb Adjustments To Additional Paid In Capital Pre Funded Warrants Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalPreFundedWarrantsIssuedIssuanceCosts
704000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
14293000
CY2024Q1 sldb Adjustments To Additional Paid In Capital Net Of Sales Commissions
AdjustmentsToAdditionalPaidInCapitalNetOfSalesCommissions
78000
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3056000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
151000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-19000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-24303000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
210724000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
211666000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2118000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
73000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-30070000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
183787000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-24303000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-30070000
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
540000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
215000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1611000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2118000
CY2024Q1 sldb Depreciation Impairment And Amortization Expense
DepreciationImpairmentAndAmortizationExpense
327000
CY2023Q1 sldb Depreciation Impairment And Amortization Expense
DepreciationImpairmentAndAmortizationExpense
1077000
CY2024Q1 us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
89000
CY2024Q1 us-gaap Other Noncash Income
OtherNoncashIncome
5000
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1337000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1261000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-596000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2745000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-260000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4911000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25192000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27995000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
149000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
506000
CY2024Q1 us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-45000000
CY2023Q1 us-gaap Payments For Proceeds From Availableforsale Securities Shortterm
PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm
-37766000
CY2024Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
83346000
CY2024Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-5000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-38490000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
37260000
CY2024Q1 sldb Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Private Placement
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPrivatePlacement
108859000
CY2024Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4825000
CY2024Q1 sldb Proceeds From Issuance Of Common Stock In Public Offering Net Of Sales Commissions
ProceedsFromIssuanceOfCommonStockInPublicOfferingNetOfSalesCommissions
3056000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
151000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
107241000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
43559000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9265000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75848000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
157217000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119407000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
166482000
CY2024Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
417000
CY2024Q1 sldb Increase Decrease In Right Of Use Asset Due To Lease Termination
IncreaseDecreaseInRightOfUseAssetDueToLeaseTermination
-197000
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
20000
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
117574000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
164649000
CY2024Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2023Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1833000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
119407000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
166482000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-683100000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-24300000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25200000
CY2024Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
206100000
CY2024Q1 us-gaap Restricted Cash
RestrictedCash
1800000
CY2024Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
178471000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
112023000
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2024Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2024Q1 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2
0
CY2023 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers In To Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersInToLevel2
0
CY2024Q1 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2
0
CY2023 sldb Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel2
0
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
88496000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2024Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
88492000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
49610000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
15000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
49625000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
88496000
CY2024Q1 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
88492000
CY2024Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
88496000
CY2024Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
88492000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsAmortizedCostBasis
49610000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
49625000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
49610000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
49625000
CY2024Q1 sldb Available For Sale Securities Weighted Average Maturity Period
AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P0Y6M
CY2023 sldb Available For Sale Securities Weighted Average Maturity Period
AvailableForSaleSecuritiesWeightedAverageMaturityPeriod
P0Y4M24D
CY2024Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19443000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
19359000
CY2024Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
13052000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
12735000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6391000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6624000
CY2024Q1 sldb Depreciation And Amortization Excluding Impairment Loss
DepreciationAndAmortizationExcludingImpairmentLoss
300000
CY2023Q1 sldb Depreciation And Amortization Excluding Impairment Loss
DepreciationAndAmortizationExcludingImpairmentLoss
700000
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
400000
CY2024Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2024Q1 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
5033000
CY2023Q4 sldb Prepaid Research And Development Expenses Current
PrepaidResearchAndDevelopmentExpensesCurrent
3980000
CY2024Q1 sldb Prepaid Expense And Other Assets Miscellaneous Current
PrepaidExpenseAndOtherAssetsMiscellaneousCurrent
3093000
CY2023Q4 sldb Prepaid Expense And Other Assets Miscellaneous Current
PrepaidExpenseAndOtherAssetsMiscellaneousCurrent
2114000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8126000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6094000
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10327000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10137000
CY2024Q1 sldb Class Of Warrant Or Rights Exercised
ClassOfWarrantOrRightsExercised
0
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1611000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2118000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-24303000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-30070000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38155373
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38155373
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19567635
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19567635
CY2024Q1 sldb Common Stock Issuable Upon Exercise Of Prefunded Warrants
CommonStockIssuableUponExerciseOfPrefundedWarrants
2712478
CY2023Q1 sldb Common Stock Issuable Upon Exercise Of Prefunded Warrants
CommonStockIssuableUponExerciseOfPrefundedWarrants
0
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.54
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.54
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4440902
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2955080
CY2022Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.18
CY2022Q4 us-gaap Severance Costs1
SeveranceCosts1
5700000
CY2024Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
100000
CY2023 us-gaap Payments For Restructuring
PaymentsForRestructuring
3700000
CY2022Q4 sldb Accrued Restructuring Costs
AccruedRestructuringCosts
3921000
CY2023 us-gaap Payments For Restructuring
PaymentsForRestructuring
3669000
CY2023Q4 sldb Accrued Restructuring Costs
AccruedRestructuringCosts
252000
CY2024Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
143000
CY2024Q1 sldb Accrued Restructuring Costs
AccruedRestructuringCosts
109000
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-060034-index-headers.html Edgar Link pending
0000950170-24-060034-index.html Edgar Link pending
0000950170-24-060034.txt Edgar Link pending
0000950170-24-060034-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img63628206_0.jpg Edgar Link pending
img63628206_1.jpg Edgar Link pending
img63628206_2.jpg Edgar Link pending
img63628206_3.jpg Edgar Link pending
img63628206_4.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sldb-20240331.htm Edgar Link pending
sldb-20240331.xsd Edgar Link pending
sldb-ex10_2.htm Edgar Link pending
sldb-ex31_1.htm Edgar Link pending
sldb-ex31_2.htm Edgar Link pending
sldb-ex32_1.htm Edgar Link pending
sldb-ex32_2.htm Edgar Link pending
sldb-20240331_htm.xml Edgar Link completed